Use of Artificial Intelligence to Identify New Mechanisms and Approaches to Therapy of Bone Disorders Associated With Chronic Kidney Disease.
artificial intelligence
chronic kidney disease
in silico clinical trials
mathematical modeling
osteoporosis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
11
2021
accepted:
28
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Chronic kidney disease (CKD) leads to clinically severe bone loss, resulting from the deranged mineral metabolism that accompanies CKD. Each individual patient presents a unique combination of risk factors, pathologies, and complications of bone disease. The complexity of the disorder coupled with our incomplete understanding of the pathophysiology has significantly hampered the ability of nephrologists to prevent fractures, a leading comorbidity of CKD. Much has been learned from animal models; however, we propose in this review that application of multiple techniques of mathematical modeling and artificial intelligence can accelerate our ability to develop relevant and impactful clinical trials and can lead to better understanding of the osteoporosis of CKD. We highlight the foundational work that informed our current model development and discuss the potential applications of our approach combining principles of quantitative systems pharmacology, model predictive control, and reinforcement learning to deliver individualized precision medical therapy of this highly complex disorder.
Identifiants
pubmed: 35402468
doi: 10.3389/fmed.2022.807994
pmc: PMC8990896
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
807994Informations de copyright
Copyright © 2022 Gaweda, Lederer and Brier.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2016 Jan 25;11(1):e0146801
pubmed: 26808154
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53
pubmed: 12819321
Artif Intell Med. 2015 Jun;64(2):131-45
pubmed: 25976208
Bone. 1996 May;18(5):397-403
pubmed: 8739896
J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):19-37
pubmed: 34671863
Semin Nephrol. 2018 Jul;38(4):397-409
pubmed: 30082059
J Am Soc Nephrol. 2014 Jan;25(1):159-66
pubmed: 24029429
J Biomed Inform. 2018 Sep;85:30-39
pubmed: 30016722
Clin J Am Soc Nephrol. 2010 May;5(5):814-20
pubmed: 20185598
Kidney Int Suppl. 2009 Aug;(113):S1-130
pubmed: 19644521
J Clin Pharmacol. 2012 Jan;52(1 Suppl):45S-53S
pubmed: 22232752
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1389-1391
pubmed: 32938618
Am J Physiol Renal Physiol. 2021 Feb 1;320(2):F203-F211
pubmed: 33308018
Clin Nephrol. 2018 Oct;90(4):276-285
pubmed: 30049300
Science. 2018 Dec 7;362(6419):1140-1144
pubmed: 30523106
Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11
pubmed: 19541818
Int J Endocrinol. 2017;2017:1659071
pubmed: 29387084
Am J Kidney Dis. 2022 Mar;79(3):427-436
pubmed: 34419519
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1445-1454
pubmed: 32938617
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59
pubmed: 30675420
Bone. 2010 Jan;46(1):49-63
pubmed: 19732857
CPT Pharmacometrics Syst Pharmacol. 2012 Nov 14;1:e14
pubmed: 23835796
Bone Rep. 2015 Apr 17;2:59-67
pubmed: 28377955
Kidney Int. 2004 Mar;65(3):904-17
pubmed: 14871410
Physiol Rep. 2019 Apr;7(7):e14045
pubmed: 30927339